David Sumerauer

TL;DR: Three distinct molecular subgroups of ATRTs, associated with differences in demographics, tumor location, and type of SMARCB1 alterations, were identified, leading to the identification of subgroup-specific regulatory networks and potential therapeutic targets.

TL;DR: The prevalence of genetic predispositions differed between molecular subgroups in the retrospective cohort and was highest for patients in the MBSHH subgroup, and survival estimates differed significantly across patients with germline mutations in different medulloblastoma predisposition genes.

TL;DR: It is concluded that infant gliomas comprise 3 subgroups, justifying the need for specialized therapeutic strategies and revealing genetic alterations which may offer therapeutic opportunities.

TL;DR: BRAF V600E PLGG constitutes a distinct entity with poor prognosis when treated with current adjuvant therapy, and additional multivariable clinical and molecular stratification revealed that the extent of resection and CDKN2A deletion contributed independently to poor outcome in BRAF V 600E PL GG.